---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References"
description: "Reference list for the formulary evidence report on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab. 135 cited documents."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References

<a id="references"></a>

## 5 References

1. [Abraham et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31581922/)
2. [Abraham et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12691436/)
3. [Aguiar-Ibáñez et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11792841/)
4. [American Cancer Society (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf)
5. [Ang et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2943767/)
6. [Argiris et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4071756/)
7. [Bedi et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3640459/)
8. [Biau et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42372755/)
9. [Bicara Therapeutics breakthrough therapy designation announcement (2025)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-ficerafusp-alfa-granted)
10. [Bicara Therapeutics clinical trial protocol BCA101X1101 (2024)](https://ascopubs.org/doi/suppl/10.1200/JCO-25-02027/suppl_file/protocol_JCO-25-02027.pdf)
11. [Bicara Therapeutics expanded access policy](https://www.bicara.com/expanded-access-policy/)
12. [Bicara Therapeutics first quarter 2026 results announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-first-quarter-2026-financial-results)
13. [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)
14. [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)
15. [Bicara Therapeutics FORTIFI-HN01 first enrollment announcement (2025)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-first-patients-enrolled-fortifi)
16. [Bicara Therapeutics fourth quarter and full year 2025 results announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-fourth-quarter-and-full-year-2025)
17. [Bicara Therapeutics phase 3 dose and 2026 outlook announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-phase-3-optimal-dose-and-provides)
18. [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4)
19. [Bicara Therapeutics second quarter 2026 results announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-second-quarter-2026-progress-and)
20. [Bicara Therapeutics third quarter 2026 results announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-third-quarter-2026-financial-results)
21. [Bicara Therapeutics three-year overall survival announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/ficerafusp-alfa-plus-pembrolizumab-demonstrated-differentiated)
22. [Black et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10241070/)
23. [Black et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10881782/)
24. [Boreddy et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10236157/)
25. [Borse et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35765888/)
26. [Bradbury et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12218434/)
27. [Britton et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11394608/)
28. [Bulbul et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/34729845/)
29. [Burtness et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31679945/)
30. [Burtness et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9287281/)
31. [Cabezas-Camarero et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12827138/)
32. [Cancer Genome Atlas Network (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4311405/)
33. [Chaturvedi et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3221528/)
34. [Chung et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.6017)
35. [ClinicalTrials.gov NCT04429542](https://clinicaltrials.gov/study/NCT04429542)
36. [ClinicalTrials.gov NCT04534205](https://clinicaltrials.gov/study/NCT04534205)
37. [ClinicalTrials.gov NCT06064877](https://clinicaltrials.gov/study/NCT06064877)
38. [ClinicalTrials.gov NCT06525220](https://clinicaltrials.gov/study/NCT06525220)
39. [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990)
40. [ClinicalTrials.gov NCT06790966](https://clinicaltrials.gov/study/NCT06790966)
41. [ClinicalTrials.gov NCT07276399](https://clinicaltrials.gov/study/NCT07276399)
42. [ClinicalTrials.gov NCT07465276](https://clinicaltrials.gov/study/NCT07465276)
43. [ClinicalTrials.gov NCT07529873](https://clinicaltrials.gov/study/NCT07529873)
44. [ClinicalTrials.gov NCT07552558](https://clinicaltrials.gov/study/NCT07552558)
45. [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163)
46. [Cohen et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30509740/)
47. [Costantino et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40211672/)
48. [Dzienis et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11361359/)
49. [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)
50. [EU CTIS 2026-526741-10-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2026-526741-10-00)
51. [Fakhry et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4195851/)
52. [Faquin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12480157/)
53. [FDA (2018)](https://www.fda.gov/media/71195/download)
54. [FDA (2023)](https://www.fda.gov/media/166431/download)
55. [FDA (2024)](https://www.fda.gov/media/164555/download)
56. [FDA (2026)](https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-amivantamab-and-hyaluronidase-lpuj-recurrent-or-metastatic-head-and)
57. [FDA List of Cleared or Approved Companion Diagnostic Devices (2026)](https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools)
58. [FDA press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-treatment-head-and-neck-squamous-cell-carcinoma)
59. [Ferrarotto et al. (2025a)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS6113)
60. [Ferrarotto et al. (2025b)](https://www.bicara.com/wp-content/uploads/2025/06/FINAL_Bicara_ASCO_TiP_Poster-1.pdf)
61. [Ferrarotto et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS6129)
62. [Ferrarotto et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Ferrarotto_2026_ASCO_Poster_FORTIFI-HN01-TiP_FINAL-APPROVED.pdf)
63. [Ferris et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5564292/)
64. [Fisher et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29530457/)
65. [Forastiere et al. (1992)](https://pubmed.ncbi.nlm.nih.gov/1634913/)
66. [Fraslin et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40848743/)
67. [Genmab LiGeR-HN1 interim analysis announcement (2026)](https://ir.genmab.com/news-releases/news-release-details/genmab-announces-statistically-significant-clinically-meaningful)
68. [Genmab petosemtamab phase 2 update announcement (2026)](https://ir.genmab.com/news-releases/news-release-details/genmab-announces-updated-phase-2-data-demonstrating-more-two)
69. [Gibson et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/15908667/)
70. [Guigay et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33684370/)
71. [Haddad et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31928375/)
72. [Hanna et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39754998/)
73. [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)
74. [Harrington et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9902012/)
75. [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)
76. [Hihara et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42203315/)
77. [ImClone ERBITUX prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf)
78. [Janot et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18936479/)
79. [Janssen RYBREVANT FASPRO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761433s002lbl.pdf)
80. [Johnson & Johnson OrigAMI-4 cohort 2 announcement (2026)](https://www.jnj.com/media-center/press-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-plus-immunotherapy-shows-strong-clinical-benefit-with-56-percent-overall-response-rate-in-first-line-recurrent-or-metastatic-head-and-neck-cancer)
81. [Johnson & Johnson OrigAMI-4 cohort 5 announcement (2026)](https://www.jnj.com/media-center/press-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-combination-demonstrates-77-overall-response-rate-in-first-line-treatment-of-patients-with-advanced-head-and-neck-cancer)
82. [Johnson et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7944998/)
83. [Kaczmar et al. (2025)](https://www.bicara.com/wp-content/uploads/2025/12/750-mg-ESMO-Asia-Congress-2025-12.6.25.pdf)
84. [Kaczmar et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6058)
85. [Kaczmar et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Kaczmar_2026_ASCO_Poster-layout_Deep-response_FINAL-APPROVED.pdf)
86. [Kao et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42742405/)
87. [Keam et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8710460/)
88. [Kim et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22475042/)
89. [Lee et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32437021/)
90. [Lee et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12099209/)
91. [Lewis et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40126379/)
92. [Li et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12083786/)
93. [Lilly ERBITUX cost information (2026)](https://www.lillypricinginfo.com/erbitux)
94. [Llop et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11625818/)
95. [Machiels et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12218485/)
96. [Machtay et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4911537/)
97. [Mady et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12163717/)
98. [Mandal et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5070962/)
99. [Massa et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6439752/)
100. [Massa et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9585466/)
101. [Mauskopf et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17888098/)
102. [Merck KEYTRUDA cost information (2026)](https://www.keytruda.com/financial-support/)
103. [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)
104. [Meregaglia and Cairns (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5581467/)
105. [Mody et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34562395/)
106. [National Cancer Institute (2021)](https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet)
107. [National Cancer Institute Laryngeal Cancer Treatment PDQ (2025)](https://www.cancer.gov/types/head-and-neck/hp/adult/laryngeal-treatment-pdq)
108. [National Cancer Institute Lip and Oral Cavity Cancer Treatment PDQ (2025)](https://www.cancer.gov/types/head-and-neck/hp/adult/lip-mouth-treatment-pdq)
109. [National Cancer Institute Oropharyngeal Cancer Treatment PDQ (2025)](https://www.cancer.gov/types/head-and-neck/hp/adult/oropharyngeal-treatment-pdq)
110. [Nguyen et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10116977/)
111. [Pfister et al. (2020)](https://jnccn.org/view/journals/jnccn/18/7/article-p873.xml)
112. [Reverdy et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37562096/)
113. [Rischin et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35381576/)
114. [SEER Cancer Stat Facts Laryngeal Cancer (2026)](https://seer.cancer.gov/statfacts/html/laryn.html)
115. [SEER Cancer Stat Facts Oral Cavity and Pharynx Cancer (2026)](https://seer.cancer.gov/statfacts/html/oralcav.html)
116. [Senkomago et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6705893/)
117. [She et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35483156/)
118. [Siegel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12798275/)
119. [Sullivan et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24438712/)
120. [Sung et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13343830/)
121. [Swiecicki et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13473864/)
122. [Tahara et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40262400/)
123. [Tortochaux et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21741720/)
124. [Vermorken et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18784101/)
125. [Wakasaki et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31128940/)
126. [WHO Drug Information Proposed INN List 130 (2023)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl130.pdf)
127. [WHO Drug Information Recommended INN List 92 (2024)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/rl92.pdf)
128. [Wissinger et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4153967/)
129. [Wong et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6040)
130. [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)
131. [Xie et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13447393/)
132. [Ye et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10957979/)
133. [Yilmaz et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.22.02328)
134. [Zandberg et al. (2026)](https://www.bicara.com/wp-content/uploads/2026/02/Zandberg_2026_MHNCS_Pres_2000-mg-Cohort_Edited.pdf)
135. [Zheng et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193321/)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
